Table 1.
Computer simulated CI and DRI values for combinations of rituximab, ULBP2:7D8 and B7-H6:7D8a
| CI values at lysis of |
DRI values at lysis of |
||||||
|---|---|---|---|---|---|---|---|
| Combination | ratio | 10% | 20% | 40% | 10% | 20% | 40% |
| rituximab + ULBP2:7D8 | 1:50 | 0.4 | 0.3 | 0.2 | 3.3 | 3.6 | 4.1 |
| 14.1 | 22.4 | 39.4 | |||||
| rituximab + B7-H6:7D8 | 1:125 | 0.5 | 0.5 | 0.6 | 2.1 | 2.0 | 1.9 |
| 13.3 | 22.6 | 43.0 | |||||
| ULBP2:7D8 + B7-H6:7D8 | 2.5:1 | 0.3 | 0.2 | 0.1 | 5.1 | 8.7 | 16.6 |
| 7.4 | 15.9 | 40.4 | |||||
| rituximab + ULBP2:7D8+B7-H6:7D8 | 1:50:125 | 0.6 | 0.4 | 0.3 | 2.2 | 3.1 | 4.6 |
| 9.4 | 19.0 | 44.4 | |||||
| 13.5 | 34.6 | 107.7 | |||||
a
Combination index (CI) and dose reduction index (DRI) were calculated from dose response curves using Ramos cells and purified NK cells for three different effect levels by computer simulation using CalcuSyn software. Upper, middle and lower DRI-values correspond to rituximab, ULBP2:7D8 and B7-H6:7D8, respectively.